295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas
Main Authors: | Hui Zhou, Ying Liu, Fang Liu, Siqing Fu, Nehal Lakhani, Marlana Orloff, Kedan Lin, Shuling Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
Monoclonal Antibodies Radiolabeling with Rhenium-188 for Radioimmunotherapy
by: Licia Uccelli, et al.
Published: (2017-01-01) -
Novel CD20 monoclonal antibodies for lymphoma therapy
by: Cang Shundong, et al.
Published: (2012-10-01) -
Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers
by: Yingnan Si, et al.
Published: (2021-08-01) -
T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody
by: Tutt, Alison L., et al.
Published: (2002) -
CD47-Blocking Antibodies and Atherosclerosis
by: John J. Ryan, MD
Published: (2016-08-01)